Progenity is a biotech company with a multi-omics approach.
We are combining genomics, epigenomics, proteomics, and metabolomics to improve the diagnosis and treatment of disease.
About UsTransforming healthcare to be more precise and personal.
Latest News
- Progenity Reduces Outstanding Debt by $20.175 Million Through a Private Exchange of $20.175 Million of Its 7.25% Convertible Senior Notes Due 2025 for Shares of Common Stock October 26, 2021
- Progenity to Participate in Crohn’s & Colitis Foundation’s Fourth Annual IBD Innovate Conference October 19, 2021
Featured Publications
- Development of a novel drug delivery system to deliver drugs directly... The DDS2 system could result in improved efficacy and reduced systemic exposure for the treatment of ulcerative colitis. Aug 30, 2021
- Targeted delivery of tofacitinib citrate to the site of disease to improve... When delivered to the site of inflammation, liquid drug formulations could result in higher tissue absorption and lower drug exposure. May 20, 2021